• Our approach
    • Our Approach
    • Nonclinical Research
    • Publications
  • Our Pipeline
    • Our Pipeline
    • The PI3K – mTOR Pathway
    • Gedatolisib
    • Expanded Access Program
  • About
    • About
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Quote
    • Stock Chart
    • Analyst Coverage
    • IR Alerts

Unraveling complexity. Harnessing insights.

  • NEWS
  • CONTACT
  • Our approach
    • Our Approach
    • Nonclinical Research
    • Publications
  • Our Pipeline
    • Our Pipeline
    • The PI3K – mTOR Pathway
    • Gedatolisib
    • Expanded Access Program
  • About
    • About
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Quote
    • Stock Chart
    • Analyst Coverage
    • IR Alerts
  • Corporate Menu
    • Our Approach
      • Our Approach
      • Nonclinical Research
      • Publications
    • Our Pipeline
      • Our Pipeline
      • The PI3K – mTOR Pathway
      • Gedatolisib
      • Expanded Access Program
    • About
      • About
      • Board of Directors
      • Scientific Advisory Board
      • Our Team
    • News
    • Contact
  • IR Menu
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committees & Documents
      • Board of Directors
      • Scientific Advisory Board
      • Our Team
    • SEC Filings
    • Stock Quote
    • Stock Chart
    • Analyst Coverage
    • IR Alerts
  • Investor Home
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Committees & Documents
    • Board of Directors
    • Scientific Advisory Board
    • Our Team
  • SEC Filings
  • Stock Quote
  • Stock Chart
  • Analyst Coverage
  • IR Alerts
Thank you.
You have been unsubscribed from our IR alerts.
© 2021 Celcuity, Inc. All rights reserved.
Licensure: CLIA ID #: 24D2098245 / CAP #: 9387225
Corporate Overview

We are a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy that leverages our CELsignia CDx platform. CELsignia is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies.

IR Menu
  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • SEC Filings
  • Stock Quote
  • Stock Chart
  • Analyst Coverage
  • IR Alerts
Contact
Celcuity Headquarters
16305 – 36th Avenue North
Suite 100
Minneapolis, MN 55446
Linkedin-in